COLORADO SPRINGS, Colo., Sept. 13 /PRNewswire-FirstCall/ --
Spectranetics Corporation (Nasdaq: SPNC) today announced it plans to appeal
the verdict in a patent litigation dispute with Dr. Peter Rentrop in the
U.S. District Court in the Southern District of New York. The preliminary
jury award of $500,000 to Dr. Rentrop has been accepted by the judge
following a review of post-trial motions. The preliminary jury award of
legal fees to Dr. Rentrop in the amount of $150,000 was denied by the
judge. Dr. Rentrop has filed motions seeking to declare this case
"exceptional" and is seeking legal fees as well as pre-judgment and
post-judgment interest. These motions have not been ruled on by the Court.

"We have now filed our notice of appeal and intend to pursue all appeal
options vigorously," said John G. Schulte, Spectranetics' President and
Chief Executive Officer. "All costs associated with the preliminary jury
verdict were accrued in our financial statements for the three and twelve
months ended December 31, 2006 and we have been and will continue accruing
a 5% royalty on all sales of Point 9 millimeter catheters, pending the
outcome of our appeal."

About Spectranetics

Founded in 1984, Spectranetics manufactures and sells the only excimer
laser approved in the United States, Europe and Japan for use in minimally
invasive cardiovascular procedures. This technology treats complex
cardiovascular conditions by photo-ablating multiple lesion types into tiny
particles that are easily absorbed into the blood stream. The Company's
disposable catheters use high-energy "cool" ultraviolet light to vaporize
arterial blockages in the legs and heart, as well as scar tissue
encapsulating pacing and defibrillation leads. For more information visit
http://www.spectranetics.com.

Safe Harbor Statement

This news release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Such statements are based on current
assumptions that involve risks and uncertainties that could cause actual
outcomes and results to differ materially. These risks and uncertainties
may include increasing price and product competition, increased pressure on
expense levels resulting from expanded marketing and clinical activities,
uncertain success of the Company's strategic direction, dependence on new
product development, intellectual property claims of third parties,
availability of inventory from suppliers, the receipt of FDA approval to
market new products or applications and the timeliness of any approvals,
the potential size of market opportunities associated with new products,
market acceptance of new products or applications, product defects,
unexpected delays or costs associated with the Company's relocation and
consolidation of its headquarters and manufacturing operations, price
volatility due to the initiation or cessation of coverage, or changes in
ratings, by securities analysts. For a further list and description of such
risks and uncertainties that could cause the actual results, performance or
achievements of the Company to be materially different from any anticipated
results, performance or achievements, please see the Company's previously
filed SEC reports. Spectranetics disclaims any intention or obligation to
update or revise any financial projections or forward-looking statements,
whether as a result of new information, future events or otherwise.

(Date:12/8/2016)... ... 2016 , ... Coppin Insurance Agency, an insurance and financial planning firm based ... Coral area, is embarking on a charity drive with the goal of providing support ... Chapin Food Bank of Southwest Florida works to provide fresh and nutritious food free ...

(Date:12/7/2016)... ... December 07, 2016 , ... Students attending Envision’s summer ... opportunity to get hands-on experience in an emergency medical simulation, When Care is ... gain invaluable, real-life medical skills that are critical success in a future career ...

(Date:12/8/2016)... Calif. , Dec. 8, 2016 IRIDEX Corporation ... to offer newly issued shares of common stock, $0.01 par ... to an underwritten public offering. The final terms of the ... time of pricing, and there can be no assurance as ... IRIDEX expects to use the net proceeds it will ...

(Date:12/8/2016)... -- The global biosurgery market is expected to grow at ... 2016 to 2021. The market is poised to reach ... in 2016. The market is primarily driven by rising ... and spinal problems, increasing clearance of biosurgery products by ... management. In this report, the biosurgery market ...